[PDI] Chen Hong: USP / BP compliance is a must or optional?

Dr Chen Hong received his Ph.D in analytical chemistry from Cleveland State University in 1996 After that, he did two years of biomedical postdoctoral research in Cleveland Clinic Foundation, the most famous Heart Foundation in the world He has 23 years of rich working and management experience in aDolor, J & J, Teva and NexGen Pharma in the United States and Yiling pharmaceutical in China He has served as the analysis and technical director of Teva, the world's largest generic pharmaceutical company, and the R & D director and senior director of NexGen Pharma in the United States He has personally led and participated in the research and development of more than 30 new drugs and generic drugs, including one class I new drug (entereg) and 11 anda solid and liquid preparation products, which have been approved and listed by the US FDA He has published, lectured and presented more than 50 scientific papers on drug development and biomedicine Currently, he is the vice president of the Research Institute of Shijiazhuang Yiling Pharmaceutical Co., Ltd and the president of the research branch of chemical and biological medicine Hebei Province "hundred talents plan" medical experts and experts specially employed by the Bureau of foreign experts Led the R & D, consistency evaluation and international preparation registration and application of chemical drugs in Yiling pharmaceutical industry, with rich experience in team building, project management, international certification, R & D quality system establishment and preparation registration and application Dr Chen Hong, vice president of Ling Pharmaceutical Research Institute and President of chemical and biological pharmaceutical research branch, held the annual "PDI" conference in the pharmaceutical industry from June 29 to 30, "the third China Pharmaceutical R & D Innovation Summit and 2018 China's top 100 pharmaceutical R & D strength list", which will be held in Chongqing Marriott Hotel This year's theme is "research and development of generic drugs in the new era" At that time, Dr Chen will bring a wonderful report entitled "how to develop high-quality injection generic drugs" Today, we'd like to share another wonderful report of Dr Chen, "USP / BP compliance is a most or optional?", hoping to help you (for another friend who needs the original PPT, please contact Yao Xiaozhi (wechat: 17318481750) to send it to you separately.)